Blockage of the Monoamine Oxidase by a Natural Compound to Overcome Parkinson's Disease via Computational Biology

Abstract

The dopamine (DA) metabolism changes are significant in Parkinson's disease (PD). Levels of monoamine oxidases (MAOs) play a critical role in DA metabolism and oxidative damage. Increased levels of the MAO-B enzyme in the elderly raise oxidative damage and enhance neurodegenerative processes. Inhibiting MAO-B as an attractive target would be the best method for treating and understanding Parkinson's disease. This study aimed to recognize a suitable inhibitor for the MAO-B enzyme using computational biology and compared it with Safinamide as a positive control. We used various computational biology techniques such as binding free energy, virtual screening, molecular dynamics (MD), and docking considerations to achieve the goal. To obtain a potent inhibitor, 41,852 compounds were taken from the Zinc database. After preparing compounds and the MAO-B enzyme, screening was performed using AutoDock Vina software. After screening, a potent natural inhibitor (ZINC00261335) was picked, and then, subsequent MD simulations for both ZINC00261335 and Safinamide were conducted via GROMACS software. The stability of the MAO-B_ZINC00261335 complex was excellent during the simulation, and the results of MM-PBSA analysis explicated that ZINC00261335 with (-118.353kJmol-1) is more potent than Safinamide (-89.305kJmol-1). Ultimately, the ADME study (lipophilicity, drug similarity and pharmacokinetic parameters) for ZINC00261335 was revealed, which is acceptable for human use. This study indicates that ZINC00261335 is a suitable MAO-B inhibitor and a great candidate for more laboratory studies.